| __timestamp | Intra-Cellular Therapies, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 10811000 |
| Thursday, January 1, 2015 | 18187286 | 33001000 |
| Friday, January 1, 2016 | 24758063 | 64936000 |
| Sunday, January 1, 2017 | 23666957 | 99909000 |
| Monday, January 1, 2018 | 30099855 | 127724000 |
| Tuesday, January 1, 2019 | 64947625 | 161524000 |
| Wednesday, January 1, 2020 | 186363444 | 182933000 |
| Friday, January 1, 2021 | 272611040 | 219982000 |
| Saturday, January 1, 2022 | 358782000 | 278139000 |
| Sunday, January 1, 2023 | 409864000 | 309799000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, operational costs are a critical factor in determining a company's financial health. Over the past decade, Intra-Cellular Therapies, Inc. and Ultragenyx Pharmaceutical Inc. have demonstrated intriguing trends in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. This reflects the company's aggressive expansion and investment in operational infrastructure.
Ultragenyx, on the other hand, experienced a more moderate growth, with SG&A expenses increasing by approximately 28 times over the same period. This suggests a more measured approach to scaling operations.
By 2023, Intra-Cellular Therapies' SG&A expenses were about 32% higher than Ultragenyx's, highlighting differing strategic priorities in managing operational costs.
Eli Lilly and Company vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: AbbVie Inc. vs Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Ultragenyx Pharmaceutical Inc.
Takeda Pharmaceutical Company Limited vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs BioMarin Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Walgreens Boots Alliance, Inc. vs Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Cytokinetics, Incorporated vs Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and MorphoSys AG
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Protagonist Therapeutics, Inc. Trends and Insights